Table 1.

Summary of 59 specimens from 23 patients

Patient	Age	Specimen		Diagnosis	Type	Submitted diagnosis	IHC
		Cytology	Histology
1	47	CC		Adenocarcinoma	Primary	N/A
			CB	GCA	Primary	N/A	Positive CK7, mCEA; negative p16, ER, PR, vimentin
2	36	CC		AGC, NOS	Recurrent	N/A
		CC		AGC, NOS	Recurrent	N/A
		CC		AGC, NOS	Recurrent	N/A
		CC		AGC, favor adenocarcinoma	Recurrent	N/A
		CC		Adenocarcinoma	Recurrent	N/A
3	46	CC		AGC, favor adenocarcinoma	Primary	N/A
			CB	Favor GCA	Primary	N/A	Positive CK7; negative CK20, ER, PR, p16, PAX8
			ECC	Favor GCA	Primary	N/A
4	63	PF		Adenocarcinoma	Primary	N/A
5	65	CC		AGC, NOS	Recurrent	N/A
6	65	PF		Positive (adenocarcinoma)	Primary	Suspicious for adenocarcinoma	Positive p53 (diffuse); negative p16, ER
			EMB	Consistent with GCA	Primary	N/A
7	83	CC		Suspicious for adenocarcinoma	Primary	Atypical glandular cells, favor neoplastic	Positive PAX8, mCEA; patchy p16; negative ER, vimentin, p53 (null)
			EMB	High grade adenocarcinoma	Primary	N/A
8	47		VB	GCA	Primary	Features of GCA and MDA	Positive CK7, mCEA; negative CK20, ER, PR, p16
			CB	GCA	Primary	N/A
			PB	GCA	Primary	N/A
		Pelvic lymph node biopsy IS		Adenocarcinoma	Recurrent	N/A
9	47	VC		Adenocarcinoma	Recurrent	N/A
			VB	Consistent with GCA	Recurrent	N/A	No, known GCA
10	41	Neck lymph node FNA		Adenocarcinoma	Metastatic	N/A
11	44	VC		Adenocarcinoma	Primary	Suspicious for adenocarcinoma	Positive CK7, CK20, PAX8; negative ER, PR, p16, CDX2, TTF1, HNF1-beta
			VB	Mucinous adenocarcinoma	Primary	N/A
12	48	CC		Adenocarcinoma	Primary	N/A
			ECC	Atypical pyloric metaplasia, suspicious for adenocarcinoma	Primary	Low grade mucinous adenocarcinoma	No, known GCA
			EMB	Atypical pyloric metaplasia, suspicious for adenocarcinoma	Primary	Atypical pyloric metaplasia, suspicious for adenocarcinoma
13	52		EMC	Suggestive of GCA	Primary	Mucin-producing adenocarcinoma	Positive CK7, CK20, CDX2, CEA, HNF1-beta, PAX8, p53 (diffuse); negative GATA3, napsin-A, p16, mammaglobin
			ECC	GCA	Primary	Mucin-producing adenocarcinoma
			CB (multiple)	GCA	Primary	Mucin-producing adenocarcinoma
		CC		Adenocarcinoma	Primary	N/A
14	64	CC		Adenocarcinoma	Primary	Adenocarcinoma, favor endometrial origin
			ECC	Consistent with GCA	Primary	Endometrioid adenocarcinoma with mucinous differentiation	Positive CEA, HNF1-beta, CA-IX; negative ER, PR, p16, vim
			EMC	Consistent with GCA	Primary	N/A
		PF		Positive (adenocarcinoma)	Metastatic	N/A
15	69		EMB	Consistent with GCA	Primary	Adenocarcinoma with clear cell features	Patchy p16; negative ER, PR
			CB	Consistent with GCA	Primary	Adenocarcinoma with clear cell features
		Pelvic mass FNA		Consistent with GCA	Metastatic	N/A
16	44		EMB	Endocervical adenocarcinoma with intestinal differentiation	Primary	N/A	Negative p16
		PF		Positive (adenocarcinoma)	Metastatic	N/A
17	68		ECC	GCA	Primary	Adenocarcinoma, moderately to poorly differentiated	Positive CK7, CA-IX, napsin-A, p53 (diffuse), PAX8 (focal); negative p16, WT1, ER
			EMC	GCA	Primary	N/A
		PF		Positive (adenocarcinoma)	Primary	Negative for malignant cells
18	52		UB	GCA	Metastatic	N/A	No, known GCA
19	64		ECC	Favor GCA	Primary	GCA with areas of MDA	No
			EMB	Favor GCA	Primary	N/A	No
			CB (multiple)	Favor GCA	Primary	N/A	No
20	29		ECC	Consistent with GCA	Primary	Mucinous adenocarcinoma, moderately differentiated	Negative p16
			EMC	Atypical mucinous epithelium	Primary	N/A
			CB (multiple)	Consistent with GCA	Primary	N/A
			BB	Consistent with GCA	Recurrent	N/A
21	54		EMC	GCA	Primary	Mucinous adenocarcinoma, well differentiated	Negative p16
22	58		ECC	GCA	Primary	Suspicious for GCA	No
			EMC	GCA	Primary	N/A	No
			CB	GCA	Primary	N/A	No
			ECC	GCA	Primary	N/A	No
23	56		CB (multiple)	GCA	Primary	GCA with usual type areas	Negative p16, vimentin, wild type p53, HPV ISH
			ECC	GCA	Primary	N/A

Abbreviations: AGC, atypical glandular cells; BB, bladder biopsy; CB, cervical biopsy; CK, cytokeratin, CC, cervical cytology; ECC, endocervical curettage; EMB, endometrial biopsy; EMC, endometrial curettage; ER, estrogen receptor; FNA, fine needle aspiration; GCA, gastric type adenocarcinoma; HNF, hepatocyte nuclear factor; HPV, human papillomavirus; IS, imprint smear; ISH, in situ hybridization; mCEA, monoclonal carcinoembryonic antigen; MDA, minimal deviation adenocarcinoma; N/A, not applicable; NOS, not otherwise specified; PB, pelvic biopsy; PF, pelvic fluid; PR, progesterone receptor; UB, umbilical biopsy; VB, vaginal biopsy; VC, vaginal cytology.

Submitted diagnosis – diagnosis made by submitting pathologists in cases submitted for consultation to our institution by external laboratories.